A Phase 3 interventional study of CR845 0.5 mcg/kg and Placebo in Uremic Pruritus, sponsored by Cara Therapeutics, Inc.. Completed at 57 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-26.
Sponsored by Cara Therapeutics, Inc. (part of Tvardi Therapeutics, Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing difelikefalin in Pruritus — 2 open to participants now, 2 under way, none of them phase 3. difelikefalin · Pruritus.
Among the 19 studies testing difelikefalin in Pruritus, this one is the 3rd largest by enrollment, is one of 3 that started in 2018, is one of 9 in phase 3, and was the 4th registered.
491 studies on the registry are indexed under Pruritus; 94 are open to participants now.
Browse Pruritus studies →2 of the 19 studies testing difelikefalin in Pruritus are open now, in 7 countries. Recruiting first, the newest first:
Vifor Fresenius Medical Care Renal Pharma · Sites in China, Greece, Israel and 4 more countries
Ages 12–18
Chittagong Medical College
Ages 18+
By country, each count listing its studies:
difelikefalin: first FDA approval 2021 (KORSUVA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 9 · Phase 3 11
First in 2014; this study’s year is marked. 3 started in 2018.
This study's enrollment of 378 is above the median of 60 across 423 interventional studies indexed under Pruritus.
Median enrollment 226 across the 19 interventional studies. Of the 17 that completed or were terminated, 9 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 19 have an industry lead sponsor. The 4 most frequent:
This study is registered under Cara Therapeutics, Inc., one of the names counted as Tvardi Therapeutics, Inc.. Under that name alone:
Cara Therapeutics, Inc. is the lead sponsor of 24 studies on the registry; none are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 5 (33%) have results posted.
15 studies in Pruritus by Tvardi Therapeutics, Inc.: none open now, none under way, none of them phase 3. Of 14 finished, 6 (43%) have results posted.
Among the 15 studies in Pruritus by Tvardi Therapeutics, Inc., this one is the 3rd largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2018, is one of 7 in phase 3, and was the 4th registered.
Tvardi Therapeutics, Inc.’s Pruritus studies by the year they started, since 2014.
1 of the studies testing difelikefalin in Pruritus that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07526324Chittagong Medical CollegeDifelikefalin for Itching in Hemodialysis Patients With Chronic Kidney Disease | 2027-01-30 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing difelikefalin in Pruritus, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Tvardi Therapeutics, Inc.’s 15 in Pruritus:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of intravenous (IV) CR845 at a dose of 0.5 mcg/kg administered after each dialysis session. The study includes a 12-week Double-blind Phase and a 52-week Open-label Extension Phase.
Double-blind Phase The Double-blind Phase of the study will consist of a Screening Visit, a 7-day Run-in Period, a 12 week Double-blind Treatment Period, and a 2-week Discontinuation Period. Informed consent will be obtained prior to performing any study-specific procedures. The Screening Visit will occur within 7 to 28 days prior to randomization to assess eligibility.
Open-label Extension Phase Patients who received at least 30 doses of study drug (either active or placebo) during the 12-week Double-blind Treatment Period and continue to meet other eligibility criteria will have the option to receive open label CR845 for an additional 52 weeks. The Open-label Extension Phase will be comprised of the Open-label Treatment Period and the Follow-up Period.
The last dose of open-label study drug will be administered at the last dialysis visit on Week 52, or Early Termination. A final safety Follow up Visit will be conducted 7-10 days after the End of Treatment/Early Termination Visit.
Key Inclusion Criteria:
To be eligible for inclusion into the Double-blind Phase of the study, a patient must meet the following criteria:
Prior to randomization:
To be eligible for inclusion into the Open-label Extension Phase of the study, each patient will have to fulfill the additional key following criteria at the time of entry into the Open-label Extension Phase:
Key Exclusion Criteria:
A patient will be excluded from the Double-blind Phase of the study if any of the following criteria are met:
A patient will be excluded from the Open-label Extension Phase of the study if any of the additional key following criteria are met at the time of entry into the Open-label Extension Phase:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
Drug: CR845 0.5 mcg/kg
IV Placebo administered after each dialysis session (3 times/week)
Drug: Placebo
Drug page: Difelikefalin
IV medication delivered three times/week
Also known as: CR845, Difelikefalin
IV medication delivered three times/week
Reduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline ≥3 Points With Respect to the Weekly Mean of the Daily 24-hour Worst Itching Intensity Numerical Rating Scale (NRS) Score at Week 12
Intensity of itch will be measured using an NRS used to indicate the intensity of the worst itching over the past 24 hours using a 0 to 10 numeric rating scale, where "0" represents "no itching" and "10" represents "worst itching imaginable". LS means estimated percent, odds ratio and P value used a logistic regression model.
Time frame: Week 12
Improvement in Itch-related Quality of Life as Assessed by the Change From Baseline in 5-D Itch Scale Score at the End of Week 12
The 5-D Itch Scale is a multidimensional questionnaire which assesses itch-related quality of life over the past 2 weeks. The questions cover five dimensions of itch including the degree, duration of itch/day, direction (improvement/worsening), disability (impact on activities such as work), and body distribution of itch. The 5-D Itch Scale has 5 questions; the total 5-D Itch Scale score ranges from 5 to 25, with higher scores indicating worse responses.
Time frame: Baseline, Week 12
Improvement in Itch-related Quality of Life as Assessed by the Change From Baseline in Total Skindex-10 Scale Score at the End of Week 12
The Skindex-10 Scale is a multidimensional questionnaire which assesses itch-related quality of life over the past week. The questions cover 3 domains: disease, mood/emotional distress, and social functioning domain. The Skindex-10 has 10 questions; the total Skindex-10 score ranges from 0 to 60. A lower total score represents better quality of life.
Time frame: Baseline, Week 12
Reduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline ≥4 Points With Respect to the Weekly Mean of the Daily 24-hour Worst Itching Intensity NRS Score at Week 12
Intensity of itch will be measured using an NRS used to indicate the intensity of the worst itching over the past 24 hours using a 0 to 10 numeric rating scale, where "0" represents "no itching" and "10" represents "worst itching imaginable". LS means estimated percent, odds ratio and P value used a logistic regression model.
Time frame: Week 12
| Milestone | Double-blind CR845 0.5mcg/kg | Double-blind Placebo | Open-label CR845 0.5 mcg/kg |
|---|---|---|---|
| Started | 189 | 189 | 0 |
| Completed | 162 | 170 | 0 |
| Not completed | 27 | 19 | 0 |
| Milestone | Double-blind CR845 0.5mcg/kg | Double-blind Placebo | Open-label CR845 0.5 mcg/kg |
|---|---|---|---|
| Started | 0 | 0 | 313 |
| Completed | 0 | 0 | 189 |
| Not completed | 0 | 0 | 124 |
Intensity of itch will be measured using an NRS used to indicate the intensity of the worst itching over the past 24 hours using a 0 to 10 numeric rating scale, where "0" represents "no itching" and "10" represents "worst itching imaginable". LS means estimated percent, odds ratio and P value used a logistic regression model.
| percentage of subjects | CR845 0.5mcg/kg | Placebo |
|---|---|---|
| Reduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline ≥3 Points With Respect to the Weekly Mean of the Daily 24-hour Worst Itching Intensity Numerical Rating Scale (NRS) Score at Week 12 | 51.0 (42.9 to 58.9) | 27.6 (20.2 to 36.6) |
The 5-D Itch Scale is a multidimensional questionnaire which assesses itch-related quality of life over the past 2 weeks. The questions cover five dimensions of itch including the degree, duration of itch/day, direction (improvement/worsening), disability (impact on activities such as work), and body distribution of itch. The 5-D Itch Scale has 5 questions; the total 5-D Itch Scale score ranges from 5 to 25, with higher scores indicating worse responses.
| score on a scale | Double-blind CR845 0.5mcg/kg | Double-blind Placebo |
|---|---|---|
| Improvement in Itch-related Quality of Life as Assessed by the Change From Baseline in 5-D Itch Scale Score at the End of Week 12 | -5.0 (-5.7 to -4.4) | -3.7 (-4.4 to -3.1) |
The Skindex-10 Scale is a multidimensional questionnaire which assesses itch-related quality of life over the past week. The questions cover 3 domains: disease, mood/emotional distress, and social functioning domain. The Skindex-10 has 10 questions; the total Skindex-10 score ranges from 0 to 60. A lower total score represents better quality of life.
| score on a scale | Double-blind CR845 0.5mcg/kg | Double-blind Placebo |
|---|---|---|
| Improvement in Itch-related Quality of Life as Assessed by the Change From Baseline in Total Skindex-10 Scale Score at the End of Week 12 | -17.2 (-19.6 to -14.7) | -12.0 (-14.5 to -9.6) |
Intensity of itch will be measured using an NRS used to indicate the intensity of the worst itching over the past 24 hours using a 0 to 10 numeric rating scale, where "0" represents "no itching" and "10" represents "worst itching imaginable". LS means estimated percent, odds ratio and P value used a logistic regression model.
| percentage of subjects | Double-blind CR845 0.5mcg/kg | Double-blind Placebo |
|---|---|---|
| Reduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline ≥4 Points With Respect to the Weekly Mean of the Daily 24-hour Worst Itching Intensity NRS Score at Week 12 | 38.9 (29.8 to 48.7) | 18.0 (12.1 to 26.0) |
Collected over The period of adverse event reporting will start after the signing of the informed consent form (ICF) through the study Follow-up Visit or Early Termination Visit (or 7 days after the last dose if no Early Termination Visit was conducted).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-blind CR845 0.5mcg/kg | 2/189 (1.1%) | 49/189 (25.9%) | 40/189 (21.2%) |
| Double-blind Placebo | 2/188 (1.1%) | 41/188 (21.8%) | 30/188 (16%) |
| Open-label CR845 0.5 mcg/kg | 22/313 (7%) | 167/313 (53.4%) | 205/313 (65.5%) |
| Event | Double-blind CR845 0.5mcg/kg | Double-blind Placebo | Open-label CR845 0.5 mcg/kg |
|---|---|---|---|
| PneumoniaInfections and infestations | 3/189 | 5/188 | 23/313 |
| Fluid overloadMetabolism and nutrition disorders | 2/189 | 4/188 | 16/313 |
| HyperkalaemiaMetabolism and nutrition disorders | 4/189 | 4/188 | 12/313 |
| Cardiac failure congestiveCardiac disorders | 1/189 | 1/188 | 11/313 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/189 | 0/188 | 11/313 |
| SepsisInfections and infestations | 3/189 | 4/188 | 10/313 |
| Metabolic encephalopathyNervous system disorders | 1/189 | 2/188 | 10/313 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/189 | 1/188 | 10/313 |
| Mental status changesPsychiatric disorders | 2/189 | 2/188 | 9/313 |
| AstheniaGeneral disorders | 2/189 | 0/188 | 8/313 |
| Event | Double-blind CR845 0.5mcg/kg | Double-blind Placebo | Open-label CR845 0.5 mcg/kg |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 18/189 | 10/188 | 61/313 |
| NauseaGastrointestinal disorders | 7/189 | 9/188 | 54/313 |
| FallInjury, poisoning and procedural complications | 6/189 | 8/188 | 50/313 |
| HypotensionVascular disorders | 7/189 | 4/188 | 49/313 |
| VomitingGastrointestinal disorders | 10/189 | 6/188 | 43/313 |
| CoughRespiratory, thoracic and mediastinal disorders | 9/189 | 4/188 | 36/313 |
| HeadacheNervous system disorders | 8/189 | 4/188 | 36/313 |
| DizzinessNervous system disorders | 13/189 | 3/188 | 35/313 |
| HyperkalaemiaMetabolism and nutrition disorders | 7/189 | 3/188 | 35/313 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 6/189 | 8/188 | 35/313 |
| Age, Continuous(years) | Double-blind CR845 0.5mcg/kg | Double-blind Placebo | Total |
|---|---|---|---|
| Mean | 58.2 ± 11.16 | 56.7 ± 13.89 | 57.5 ± 12.6 |
| Sex: Female, Male(Participants) | Double-blind CR845 0.5mcg/kg | Double-blind Placebo | Total |
|---|---|---|---|
| Female | 77 | 70 | 147 |
| Male | 112 | 119 | 231 |
| Race (NIH/OMB)(Participants) | Double-blind CR845 0.5mcg/kg | Double-blind Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 6 | 5 | 11 |
| Asian | 6 | 7 | 13 |
| Native Hawaiian or Other Pacific Islander | 2 | 4 | 6 |
| Black or African American | 82 | 76 | 158 |
| White | 91 | 93 | 184 |
| More than one race | 1 | 2 | 3 |
| Unknown or Not Reported | 1 | 2 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2018 to primary completion in Apr 2019, 13 months.
Results were first posted in Apr 2022, 3 years after primary completion. A results delay was requested in Jul 2020.
Of 42 industry-sponsored phase 3 interventional studies under Pruritus, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 26. This study's 13 months is below that.
Counting every sponsor, half of 48 studies reached it within 19 months; a quarter within 12 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Difelikefalin